Cargando…
Molecular docking analysis of lupeol with different cancer targets
Lupeol is one of the secondary metabolite (triterpenoid) present in many medicinally effective plants. It has numerous biological and pharmacological actions. Lupeol is found to have effective herbs and has immense biological activity against several diseases including its cytotoxic effect on cancer...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Biomedical Informatics
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722432/ https://www.ncbi.nlm.nih.gov/pubmed/36518133 http://dx.doi.org/10.6026/97320630018134 |
_version_ | 1784843973658935296 |
---|---|
author | Gunasekaran, Mahalakshmi Ravi, Ravali Subramanian, Kavimani |
author_facet | Gunasekaran, Mahalakshmi Ravi, Ravali Subramanian, Kavimani |
author_sort | Gunasekaran, Mahalakshmi |
collection | PubMed |
description | Lupeol is one of the secondary metabolite (triterpenoid) present in many medicinally effective plants. It has numerous biological and pharmacological actions. Lupeol is found to have effective herbs and has immense biological activity against several diseases including its cytotoxic effect on cancer cells. In recent drug designing, molecular study of analysis is usually used for understanding the target and the ligand interaction. Therefore, it is of interest to document the molecular docking analysis data of lupeol with different cancer targets such as Caspase- 3, BCL-2, Topoisomerase, PTK, mTOR, H-Ras, PI3K, and AKT. These molecular docking studies were carried out by using AutoDock tools 4.2 version software. Molecular docking analyses of lupeol with target protein were found to have good dock score and minimum inhibition constant. BCL-2, Topoisomerase, PTK, mTOR and PI3Kdocking studies showed the best binding energy inhibition constant and ligand efficiency. The in-silico molecular docking analysis showed that the lupeol having relatively good docking energy, affinity and efficiency towards the active macromolecule, thus it may be considered as good inhibitor of proliferating cancer cells. By this knowledge of docking results, the lupeol can be used as promising drug for anticancer activity. |
format | Online Article Text |
id | pubmed-9722432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Biomedical Informatics |
record_format | MEDLINE/PubMed |
spelling | pubmed-97224322022-12-13 Molecular docking analysis of lupeol with different cancer targets Gunasekaran, Mahalakshmi Ravi, Ravali Subramanian, Kavimani Bioinformation Research Article Lupeol is one of the secondary metabolite (triterpenoid) present in many medicinally effective plants. It has numerous biological and pharmacological actions. Lupeol is found to have effective herbs and has immense biological activity against several diseases including its cytotoxic effect on cancer cells. In recent drug designing, molecular study of analysis is usually used for understanding the target and the ligand interaction. Therefore, it is of interest to document the molecular docking analysis data of lupeol with different cancer targets such as Caspase- 3, BCL-2, Topoisomerase, PTK, mTOR, H-Ras, PI3K, and AKT. These molecular docking studies were carried out by using AutoDock tools 4.2 version software. Molecular docking analyses of lupeol with target protein were found to have good dock score and minimum inhibition constant. BCL-2, Topoisomerase, PTK, mTOR and PI3Kdocking studies showed the best binding energy inhibition constant and ligand efficiency. The in-silico molecular docking analysis showed that the lupeol having relatively good docking energy, affinity and efficiency towards the active macromolecule, thus it may be considered as good inhibitor of proliferating cancer cells. By this knowledge of docking results, the lupeol can be used as promising drug for anticancer activity. Biomedical Informatics 2022-03-31 /pmc/articles/PMC9722432/ /pubmed/36518133 http://dx.doi.org/10.6026/97320630018134 Text en © 2022 Biomedical Informatics https://creativecommons.org/licenses/by/3.0/This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License. |
spellingShingle | Research Article Gunasekaran, Mahalakshmi Ravi, Ravali Subramanian, Kavimani Molecular docking analysis of lupeol with different cancer targets |
title | Molecular docking analysis of lupeol with different cancer targets |
title_full | Molecular docking analysis of lupeol with different cancer targets |
title_fullStr | Molecular docking analysis of lupeol with different cancer targets |
title_full_unstemmed | Molecular docking analysis of lupeol with different cancer targets |
title_short | Molecular docking analysis of lupeol with different cancer targets |
title_sort | molecular docking analysis of lupeol with different cancer targets |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722432/ https://www.ncbi.nlm.nih.gov/pubmed/36518133 http://dx.doi.org/10.6026/97320630018134 |
work_keys_str_mv | AT gunasekaranmahalakshmi moleculardockinganalysisoflupeolwithdifferentcancertargets AT raviravali moleculardockinganalysisoflupeolwithdifferentcancertargets AT subramaniankavimani moleculardockinganalysisoflupeolwithdifferentcancertargets |